Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy
A reactive oxygen species (ROS)-responsive prodrug strategy is developed by conjugating paclitaxel and the TLR7/8 agonist resiquimod with a phenylboronic ester (PBE) moiety to generate two ROS-activatable prodrugs, PTX–PBE and R848–PBE.